298 words
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt
Investing.com -- Shares of Bristol-Myers Squibb Co. (NYSE: BMY) fell 2.5% in premarket trading after Leerink Partners downgraded the pharmaceutical giant from Outperform to Market Perform, citing growing skepticism surrounding key candidates in the company's drug development pipeline. Before you buy…